Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy

NCT02654223 is registered in ClinicalTrials.gov with Inmunotek S.L. as lead sponsor.

NCT NCT02654223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02654223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Lead sponsor
Inmunotek S.L.
Phase
Phase 2
Overall status
Completed
Start date
December 30, 2015
Completion date
November 30, 2021
Enrollment
180 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

rhinitis, rhinoconjunctivitis